Rankings
▼
Calendar
NTLA
Intellia Therapeutics, Inc.
$2B
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
Gross Profit
-$3M
-76.5% margin
Operating Income
-$7M
-165.1% margin
Net Income
-$7M
-164.1% margin
EPS (Diluted)
$-0.36
QoQ Revenue Growth
+136.7%
Cash Flow
Operating Cash Flow
$68M
Free Cash Flow
$66M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$311M
Total Liabilities
$87M
Stockholders' Equity
$224M
Cash & Equivalents
$301M
← FY 2016
All Quarters
Q3 2016 →
NTLA Q2 2016 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
